[Skip to Content]
[Skip to Content Landing]
November 11, 1905


JAMA. 1905;XLV(20):1502. doi:10.1001/jama.1905.02510200048007

The descensus Averni of therapeutics is not a purely American phenomenon. In Germany and Austria pathology has made such splendid strides and has attracted so much attention that it has monopolized interest to an extent that has entailed neglect of therapeutics. The same tendency has played a minor part in this country, and to that extent has emphasized the opportunity of the drug makers and nostrum makers to become our preceptors in therapeutics.

In England the profession suffers nearly as much as we do, and largely from the same source. International comity has progressed at least far enough for us fully to sympathize with the plaint which appears in the British Medical Journal for Oct. 21, 1905. Our contemporary, in its editorial caption, asks: "Shall we take our therapeutics from the druggist?" Its text is a circular from an American drug firm, which instructs physicians in the several physiologic actions

First Page Preview View Large
First page PDF preview
First page PDF preview